Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Medical Officer | February 22, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date February 22, 2024 · Filed February 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,111 |
Reported balance
After 2024-02-22 transaction · row 1
1 source rowRow 1 · 2024-02-22 · Sale · Disposed 14,568 · Balance 250,111 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $37.79 | $283,411.50 |
DisclosureSEC source: 0001209191-20-040662 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 9,722 | $5.18 | $50,311.35 |
DisclosureSEC source: 0001209191-20-040662 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,778 | $1.58 | $4,375.35 |
DisclosureSEC source: 0001209191-20-040662 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,314 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-20-042652 · doc4.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,024 Underlying: Common Stock · 2,314 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| July 01, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,186 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-042652 · doc4.xml · derivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,147 Underlying: Common Stock · 10,186 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-20-037646 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,110 Underlying: Common Stock · 12,500 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $37.26 | $279,472.50 |
DisclosureSEC source: 0001209191-20-037646 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $37.27 | $186,342.00 |
DisclosureSEC source: 0001209191-20-037646 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 12,500 | $5.18 | $64,687.50 |
DisclosureSEC source: 0001209191-20-037646 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-20-034452 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,610 Underlying: Common Stock · 12,500 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $35.06 | $262,932.00 |
DisclosureSEC source: 0001209191-20-034452 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $35.09 | $175,455.00 |
DisclosureSEC source: 0001209191-20-034452 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 20:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 12,500 | $5.18 | $64,687.50 |
DisclosureSEC source: 0001209191-20-034452 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 00:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-20-025177 · doc4.xml · derivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,333 Underlying: Common Stock · 8,000 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the 111,111 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. The aggregate number of shares subject to the stock option has been reduced by one share to 111,110 shares due to rounding in connection with a partial exercise of the stock option and a reverse stock split effected prior to the Issuer's initial public offering. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 00:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 8,000 | $0.86 | $6,840.00 |
DisclosureSEC source: 0001209191-20-025177 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.